This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LOXO Loxo Oncology (LOXO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Loxo Oncology Stock (NASDAQ:LOXO) 30 days 90 days 365 days Advanced Chart Get Loxo Oncology alerts:Sign Up Key Stats Today's Range$234.66▼$234.6650-Day Range N/A52-Week Range$101.70▼$234.93Volume400 shsAverage Volume565,561 shsMarket Capitalization$7.18 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut. Read More Receive LOXO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Loxo Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LOXO Stock News HeadlinesLoxo Oncology’s Pirtobrutinib Study: A Potential Game-Changer for CLL/SLL TreatmentAugust 22, 2025 | tipranks.comEli Lilly begins executive search as neuro chief Anne White retiresAugust 20, 2025 | msn.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 29 at 2:00 AM | Brownstone Research (Ad)Small Lymphocytic Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2025 | DelveInsightJuly 24, 2025 | theglobeandmail.comLoxo Oncology’s Pirtobrutinib Study: A Potential Game-Changer for CLL/SLL TreatmentJuly 16, 2025 | tipranks.comIs Eli Lilly and Company Stock Underperforming the Dow?May 29, 2025 | msn.comGastrointestinal Stromal Tumor Market to Grow Rapidly During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsightApril 15, 2025 | finance.yahoo.comBlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice PresidentJanuary 6, 2025 | finance.yahoo.comSee More Headlines LOXO Stock Analysis - Frequently Asked Questions How were Loxo Oncology's earnings last quarter? Loxo Oncology Inc (NASDAQ:LOXO) posted its quarterly earnings data on Thursday, August, 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.15. The biopharmaceutical company earned $42.60 million during the quarter, compared to analyst estimates of $32.36 million. Loxo Oncology had a negative trailing twelve-month return on equity of 16.42% and a negative net margin of 43.49%. What other stocks do shareholders of Loxo Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Loxo Oncology investors own include Meta Platforms (META), Bristol Myers Squibb (BMY), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), GW Pharmaceuticals (GWPH) and Micron Technology (MU). Company Calendar Last Earnings8/09/2018Today8/29/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:LOXO CIK1581720 Webwww.loxooncology.com Phone203-653-3880FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($5.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$148.87 million Net Margins-43.49% Pretax MarginN/A Return on Equity-16.42% Return on Assets-8.66% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual Sales$21.30 million Price / Sales337.23 Cash FlowN/A Price / Cash FlowN/A Book Value$12.63 per share Price / Book18.58Miscellaneous Outstanding Shares30,610,000Free FloatN/AMarket Cap$7.18 billion OptionableOptionable Beta2.51 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:LOXO) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Loxo Oncology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Loxo Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.